ID
28373
Descripción
This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment). Sponsor / Information provided by (Responsible Party): Boehringer Ingelheim. https://clinicaltrials.gov/ct2/show/NCT02239120?term=NCT02239120&cond=NCT02239120&rank=1
Link
https://clinicaltrials.gov/ct2/show/NCT02239120?term=NCT02239120&cond=NCT02239120&rank=1
Palabras clave
Versiones (1)
- 8/1/18 8/1/18 -
Titular de derechos de autor
Boehringer Ingelheim
Subido en
8 de enero de 2018
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility criteria RE-SPECT ESUS Embolic Stroke NCT02239120
Eligibility criteria RE-SPECT ESUS Embolic Stroke NCT02239120
- StudyEvent: ODM
Descripción
Exclusion criteria
Descripción
Modified Rankin Scale
Tipo de datos
boolean
Descripción
such as: a) intracardiac thrombus as evidenced by transthoracic or transesophageal echocardiography, b) paroxysmal, persistent or permanent AF, c) atrial flutter, d) prosthetic cardiac valve (mitral or aortic, bioprosthetic or mechanical), e) atrial myxoma, f) other cardiac tumors, g) moderate or severe mitral stenosis, h) recent (< 4weeks) myocardial infarction, i) valvular vegetations, or j) infective endocarditis
Tipo de datos
boolean
Descripción
anticoagulant
Tipo de datos
boolean
Descripción
History of atrial fibrillation
Tipo de datos
boolean
Descripción
i.e. cerebral arteritis or arterial dissection, migraine with aura/vasospasm, drug abuse
Tipo de datos
boolean
Descripción
Renal impairment with estimated creatinine clearance (as calculated by Cockcroft-Gault equation) <30mL/min at screening, or where Investigator expects creatinine clearance is likely to drop below 30mL/min during the course of the study
Tipo de datos
boolean
Similar models
Eligibility criteria RE-SPECT ESUS Embolic Stroke NCT02239120
- StudyEvent: ODM